The pridopidine paradox in Huntington's disease.

Item

http://www.wikidata.org/entity/Q45294030

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

The pridopidine paradox in Huntington's disease.

@en

The pridopidine paradox in Huntington's disease.

@nl

type

Item

label

The pridopidine paradox in Huntington's disease.

@en

The pridopidine paradox in Huntington's disease.

@nl

prefLabel

The pridopidine paradox in Huntington's disease.

@en

The pridopidine paradox in Huntington's disease.

@nl

P1476

The pridopidine paradox in Huntington's disease.

@en

P2860

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

In vivo pharmacology of the dopaminergic stabilizer pridopidine.

Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.

The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats.

Tapping linked to function and structure in premanifest and symptomatic Huntington disease

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors.

The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties.

P304

1321-1324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/MDS.25559

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ralf Reilmann

P577

2013-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23847099

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease